Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany.
Department of Medical Oncology, Hospitals Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
Ultraschall Med. 2022 Oct;43(5):514-521. doi: 10.1055/a-1593-4401. Epub 2022 Feb 28.
The role of EUS before or after neoadjuvant chemotherapy (nCTX) in advanced esophagogastric cancer (EGC) is still unclear. The phase II NEOPECX trial evaluated perioperative chemotherapy with or without panitumumab in this setting. The aim of this sub-study was to investigate the prognostic value of EUS-guided preoperative staging before and after nCTX.
Preoperative yuT/yuN stages by EUS were compared with histopathological ypT/ypN stages after curative resection. Reduction in T-stage from baseline to preoperative EUS was defined as downstaging (DS+) and compared to progression-free (PFS) and overall survival (OS) of patients without downstaging (DS-). In addition, preoperative EUS N-stages (positive N+ or negative N-) were correlated with clinical data.
The preoperative yuT-stage correlated with the ypT-stage in 48% of cases (sensitivity 48%, specificity 52%), while the preoperative yuN-stage correlated with the ypN-stage in 64% (sensitivity 76%, specificity 52%). Within DS+ patients who were downstaged by ≥ 2 T-categories, a trend towards improved OS was detected (median OS DS+: not reached (NR), median OS DS-: 38.5 months (M), p=0.21). Patients with yuN+ at preoperative EUS had a worse outcome than yuN- patients (median OS yuN-: NR, median OS yuN+: 38.5 M, p = 0.013).
The diagnostic accuracy of EUS to predict the response after nCTX in patients with advanced EGC is limited. In the current study the endosonographic detection of lymph node metastasis after nCTX indicates a poor prognosis. In the future, preoperative EUS with sectional imaging procedures may be used to tailor treatment for patients with advanced EGC.
在进展期胃食管交界癌(EGC)中,新辅助化疗(nCTX)前后 EUS 的作用尚不清楚。II 期 NEOPECX 试验评估了该情况下围手术期化疗联合或不联合 panitumumab 的效果。本亚研究的目的是探讨 nCTX 前后 EUS 引导术前分期的预后价值。
比较根治性切除术后 EUS 引导的术前 yuT/yuN 分期与组织病理学 ypT/ypN 分期。与未降期(DS-)患者相比,基线至术前 EUS 时 T 分期下降定义为降期(DS+),并比较患者的无进展生存期(PFS)和总生存期(OS)。此外,还将术前 EUS N 分期(阳性 N+或阴性 N-)与临床数据相关联。
48%的病例中,术前 yuT 分期与 ypT 分期相关(敏感性 48%,特异性 52%),而术前 yuN 分期与 ypN 分期相关的比例为 64%(敏感性 76%,特异性 52%)。在降期≥2 个 T 分期的 DS+患者中,OS 有改善的趋势(DS+患者的中位 OS:未达到(NR),DS-患者的中位 OS:38.5 个月(M),p=0.21)。术前 EUS 中 yuN+的患者比 yuN-的患者预后更差(yuN-患者的中位 OS:NR,yuN+患者的中位 OS:38.5 M,p=0.013)。
EUS 预测进展期 EGC 患者 nCTX 后反应的诊断准确性有限。在本研究中,nCTX 后淋巴结转移的内镜超声检测提示预后不良。未来,术前 EUS 联合影像学检查可能用于为进展期 EGC 患者制定治疗方案。